Cinctive Capital Management’s Novartis NVS Stock Holding History

Cinctive Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-47,144	Closed	-$3.98M	–	563
2022 Q2	$3.98M	Buy	47,144 +2,144	+5%	+$188K	0.17%	199
2022 Q1	$3.95M	Buy	+45,000	New	+$3.9M	0.15%	228

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Cinctive Capital Management's NVS Position: Q3 2022 in Review

Cinctive Capital Management sold out of Novartis (NVS) in Q3 2022, closing a stake of 47,144 shares — an estimated $3.98M sold.

Cinctive Capital Management first reported a position in NVS in Q1 2022 and held it in 2 quarters. The position peaked at $3.98M in Q2 2022. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.

Cinctive Capital Management reported no remaining Novartis position as of Q3 2022 after selling out during the quarter.
Cinctive Capital Management sold 47,144 Novartis shares in Q3 2022, an estimated $3.98M.
Cinctive Capital Management first reported a position in Novartis in Q1 2022 and held it in 2 quarters.
Cinctive Capital Management's Novartis position peaked at $3.98M in Q2 2022.
1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.

Based on Cinctive Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.